Completed PHASE1 INTERVENTIONAL 3-arm NCT02547792

Assessment of an Oral Influenza B Vaccine Tablet (VXA-BYW.10) Following Single Dose Administration in Healthy Adults

Phase 1 , Placebo-Controlled, Dose-Ranging Trial to Determine Safety and Immunogenicity of an Oral Adenoviral-Vector Based Influenza B Vaccine

Sponsor: Vaxart

Conditions Seasonal Influenza B

Interventions Placebo Tablets VXA-BYW.10 (High Dose) Oral Vaccine VXA-BYW.10 (Low Dose) Oral Vaccine

Updated 7 times since 2017 Last updated: May 29, 2018 Started: Oct 20, 2015 Primary completion: Nov 21, 2016 Completion: Nov 21, 2016

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE1 trial investigates Seasonal Influenza B and is currently completed. Vaxart leads this study, which shows 7 recorded versions since 2015 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

Status: Active Not Recruiting → Completed
Jun 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2017 [monthly]

Active Not Recruiting PHASE1
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE1

First recorded

Oct 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Vaxart

Data source: Vaxart

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Christchurch, New Zealand